IDEA Collider: Innovation & Asymmetric Learning in Pharma

In this episode of IDEA Collider, we are joined by Alex Telford, a biotech founder, writer, and thinker based in the San Francisco Bay Area. As the co-founder of Convoke Bio, Alex discusses his journey from studying biochemistry at UCL to founding a company that develops software tools for streamlining biopharmaceutical workflows.The conversation dives into the impact of AI and language models on the biotech industry, addressing inefficiencies in drug development, and exploring the potential of synthetic biology and personalized medicine. The discussion also touches on the future of drug discovery, China's role in biotech, and the challenges of understanding neuroscience and consciousness. Don't miss this insightful discussion on the future of biopharma innovation! 00:00 Welcome to Idea Collider00:04 Introducing Alex Telford01:59 Alex's Journey from UCL to Convoke Bio05:29 The Mission and Work of Convoke Bio07:57 Challenges in Pharma Decision Making14:05 The Role of AI in Pharma18:26 Knowledge Management and AI27:58 Staying Updated in the Fast-Moving AI Field30:25 AI's Impact on Industry Economics31:38 AI in Clinical Trials and Drug Development35:56 China's Role in Drug Discovery39:24 Neuroscience and AI: Blurring the Lines46:05 Future Predictions in Pharma51:20 Addressing Cognitive Bias in Pharma53:13 Concluding Thoughts and Future Directions Keep up with Alex Telford;LinkedIn: https://www.linkedin.com/in/alexander-telford/Website: atelfo.github.ioX: https://twitter.com/atelfoSubstack: atelfo.substack.com Follow Mike Rea On;Website: https://www.ideapharma.com/X: https://x.com/ideapharmaLinkedIn: https://www.linkedin.com/in/bigidea/ Listen to more fantastic podcast episodes: https://podcast.ideapharma.com/

In this episode of Idea Collider, host Mike Rea interviews Dr. Christian Rommel from Bayer. Dr. Rommel discusses his journey in molecular oncology from the Max Planck Institute, through roles at Roche, to overseeing global R&D at Bayer. He shares insights on turning scientific discovery into novel medicines, collaboration between scientists and commercial teams, and the importance of maintaining scientific integrity. Dr. Rommel also delves into the impact of AI in drug development, the potential of genetic medicines, and the complexities of launching new medicines on a global scale. The conversation also touches on embracing failure, internal and external partnerships, and the evolving landscape of clinical translation. 00:00 Introduction and Guest Welcome00:25 Christian Rommel's Journey in Oncology03:02 The Importance of Collaboration in Innovation05:16 Balancing Risk and Reward in Drug Development18:07 The Role of AI and Data in Modern R&D22:33 Partnerships and External Learning26:16 Balancing Legacy and Innovation in Biotech27:18 Global Expansion and Leadership Diversity27:27 Courage in Biotech Management27:54 Inspiration from Roche Genentech30:26 Commitment to Product Supply and Market Readiness32:23 Challenges of Global Launches35:53 Emerging Trends in Pharma: AI and Genetic Medicines42:20 Decision-Making in Pharma47:30 Reflections on Academic and Professional Journey Don't forget to Like, Share, Subscribe, Rate, and Review! Keep up with Christian Rommel;LinkedIn: https://www.linkedin.com/in/christian-rommel/Website: https://www.bayer.com/en/innovation/science-research-and-innovation Follow Mike Rea On;Website: https://www.ideapharma.com/X: https://x.com/ideapharmaLinkedIn: https://www.linkedin.com/in/bigidea/ Listen to more fantastic podcast episodes: https://podcast.ideapharma.com/

In this insightful episode of IDEA Collider, Mike welcomes Mathai Mammen, Chairman and CEO of Parabilis Medicines. Mathai shares his extensive journey through academia, MD PhD program at Harvard, co-founding Theravance, and leadership roles at Merck and J&J. They delve into Mathai's innovative approach to creating transformative medicines, navigating the biotech industry, and the unique challenges of targeting 'undruggable' proteins. They also discuss the role of AI in drug discovery, the importance of strategic risk, and fostering team resilience and spirit in both large and small pharma companies. 00:00 Introduction and Guest Background00:56 Founding Thebans and Career Highlights01:43 Leadership at Merck and J&J02:18 Innovative Approaches at Parabilis Medicines04:09 Defining and Tackling Undruggable Targets09:27 Multivalent Drug Design and Bispecifics13:53 AI and Data Science in Drug Development19:28 Building and Leading World-Class Teams25:41 The Importance of Holding Conviction as an Entrepreneur26:25 Learning from Setbacks in the Biotech Industry30:10 Challenges and Innovations in Drug Development32:28 Navigating the Ups and Downs of the Biotech Industry36:02 The Mission and Future of Parabilis40:35 Personal Reflections and Advice for Entrepreneurs46:46 Book Recommendations and Closing Thoughts Don't forget to Like, Share, Subscribe, Rate, and Review! Keep up with Mathai Mammen;LinkedIn: https://www.linkedin.com/in/mathai-mammen/Website: https://parabilismed.com/ Follow Mike Rea On;Website: https://www.ideapharma.com/X: https://x.com/ideapharmaLinkedIn: https://www.linkedin.com/in/bigidea/ Listen to more fantastic podcast episodes: https://podcast.ideapharma.com/

In this episode of Idea Collider, host Mike Rea interviews Paul Peter Tak, CEO of Candel Therapeutics, discussing his remarkable journey from a clinician in Amsterdam to leading cutting-edge biotech companies. Paul shares pivotal moments in his career, the challenges of transitioning from academia to big pharma, and the innovative principles he applied. He dives deep into Candel’s promising work in viral immunotherapies for cancers and the unique leadership and management philosophies that have guided his journey. Additionally, Paul Peter touches on his passion for leveraging collective intelligence and his unconventional hobbies that keep him grounded and creative. 00:00 Introduction and Guest Welcome00:59 Early Career and Passion for Medicine02:09 Transition to Industry and GSK Experience04:50 Building Successful Organizations07:42 Innovative Models in Pharma19:03 Joining Candel Therapeutics and Vision for the Future25:15 Transforming Cancer Treatment27:24 Challenges in Biotech Market28:45 Strategic Decisions and Prioritization31:39 Collaborations and External Partnerships33:07 Innovative Approaches and Future Prospects44:23 Leadership and Personal Insights Don't forget to Like, Share, Subscribe, Rate, and Review! Keep up with Paul Peter Tak;LinkedIn: https://www.linkedin.com/in/paul-peter-tak-md-phd-fmedsci-1b44749/ Follow Mike Rea On;Website: https://www.ideapharma.com/X: https://x.com/ideapharmaLinkedIn: https://www.linkedin.com/in/bigidea/ Listen to more fantastic podcast episodes: https://podcast.ideapharma.com/

In this episode of Idea Collider, we sit down with Susan Galbraith from AstraZeneca, a leading figure in oncology R&D. Susan shares her journey from medical training in Manchester and Cambridge to spearheading transformative cancer treatments at AstraZeneca. She discusses pivotal moments in her career, AstraZeneca's vision for eliminating cancer as a cause of death, the role of patient stories in motivating R&D efforts, and the integration of emerging technologies like AI and digital health tools.  With a focus on collaboration and continuous learning, Susan provides insights into how successful oncology drugs are developed and the importance of equitable representation in clinical trials. Stay tuned for an engaging conversation that highlights the future of personalized cancer therapies and the collaborative efforts driving innovations in oncology.Chapter Summaries;00:00 Introduction and Guest Welcome00:27 Susan Galbraith's Career Journey02:37 Defining Success in Oncology R&D05:01 Early Phase Drug Development07:09 Digital Health and Patient Experience12:37 Global Collaboration and Innovation15:05 AI and Future of Oncology28:08 Diversity and Inclusion in Clinical Trials33:46 Mentorship and Career Advice37:45 Challenges and Future Outlook in Oncology42:06 Closing Remarks and Call to Action Don't forget to Like, Share, Subscribe, Rate, and Review! Keep up with Susan Gabraith;LinkedIn: https://www.linkedin.com/in/susan-galbraith-584a195/?originalSubdomain=uk Follow Mike Rea On;Website: https://www.ideapharma.com/X: https://x.com/ideapharmaLinkedIn: https://www.linkedin.com/in/bigidea/ Listen to more fantastic podcast episodes: https://podcast.ideapharma.com/

In this episode of IDEA Collider, we dive into the world of biotech innovation with John Maraganore, former CEO of Alnylam Pharmaceuticals. Recognized as a trailblazer, John transformed RNA interference from a scientific concept into a revolutionary class of medicines, leading the development of five life-changing drugs. Join us as we explore John's journey from a first-generation American with Greek immigrant parents to a key figure in biomedicine. We'll discuss his education at the University of Chicago, his leadership role at Alnylam, drug delivery challenges for RNAi therapeutics, and the importance of strategic pharmaceutical alliances. John also shares his take on the current biotech environment, the impact of policy and regulation, and the promising future of genetic medicines and AI in drug discovery. Chapter Summaries;00:00 Introduction to John Maraganore: Biotech Trailblazer01:11 John's Early Life and Education03:09 Joining Alnylam and the RNAi Revolution04:56 Challenges and Successes at Alnylam06:47 Current Biotech Funding Environment08:17 Global Competition and US Leadership in Biotech10:25 The Importance of In-Person Collaboration12:01 Overcoming Drug Delivery Hurdles15:21 Maintaining an Entrepreneurial Spirit in Biotech17:00 Balancing Science and Business in Decision Making20:27 Strategic Partnerships in Biotech23:36 The Role of Biotech in Global Challenges26:25 Advocating for Policy Changes in Biotech30:41 Mentoring the Next Generation of Biotech Leaders32:35 Future Frontiers in Biotech Innovation36:08 John's Vision for the Future of Biomedicine37:18 Communicating Innovation and LeadershipDon't forget to Like, Share, Subscribe, Rate, and Review! Keep up with John Maraganore;LinkedIn: https://www.linkedin.com/in/john-maraganore/ Follow Mike Rea On;Website: https://www.ideapharma.com/X: https://x.com/ideapharmaLinkedIn: https://www.linkedin.com/in/bigidea/ Listen to more fantastic podcast episodes: https://podcast.ideapharma.com/

We are excited to tell you more about the IDEA Pharma and Exploristics partnership. IDEA’s COO, Jacqui Barendregt, asked Exploristics Founder and CEO Aiden Flynn five key questions about the innovative service model and, most importantly, the value to the pharmaceutical industry this newly formed partnership will bring.

Welcome to another episode of Idea Collider with your host, Mike Rea. In this engaging conversation, we delve into the world of pharmaceutical innovation and collaboration. Our guest, Dr. Nedim Pipic, a pharmaceutical expert specializing in mental and retinal health, shares his journey and passion for making a difference. Join us as we explore the unmet needs in these areas, the power of hybrid approaches and precision psychiatry, and the integration of digital therapeutics. Discover how the industry is transforming lives through innovation while remaining patient-centric. With insights into measuring development quality, the advantages of being a private company, and the importance of collaboration, this episode will inspire you to embrace change and drive positive outcomes in the pharmaceutical landscape. Tune in to Idea Collider today and be part of the movement toward a healthier, sustainable, and equitable future. Chapter Summaries [0:00:21] Introduction to today's guest, Dr. Nedim Pipic [0:04:23] Discussion on Innovation and Growth Mindset [0:06:44] Innovation and Patient Benefit in the Pharmaceutical Industry: A Discussion on the Importance of Return on Invention and Understanding Unmet Needs in Mental Health [0:08:25] Innovating Mental Health: A Discussion on Precision Psychiatry and Unmet Patient Needs [0:14:39] A Discussion on Precision Medicine and the Importance of Understanding Neurobiology in Addressing Symptoms [0:16:39] Driving Innovation in Pharma: Importance of Early Research Collaborations and Agile Culture [0:18:52] Discussion on Innovation and R&D in Pharmaceutical Industry [0:20:22] Driving Innovation and Culture in a Private Pharmaceutical Company [0:23:41] Insights on Innovation and Transformation [0:25:46] The Importance of Seeking Inspiration Outside of the Pharma Industry: A Conversation on AI and Agile Transformation [0:27:04] A Discussion on the Intersection of Medicine and Business in Pharmaceutical Innovation [0:33:28] Discussion on the Future of the Pharma and Biotech Industry and the Importance of Innovation and Collaboration [0:36:06] The Future of the Pharma Industry: Collaboration, Patient Empowerment, and Sustainability [0:37:39] Closing Remarks Don't forget to Like, Share, Subscribe, Rate, and Review! Keep up with Dr. Nedim Pipic; ● LinkedIn: https://www.linkedin.com/in/nedim-pip... ● Website: http://www.boehringer-ingelheim.com Follow Mike Rea On; ● Website: https://www.ideapharma.com/ ● Twitter: https://twitter.com/ideapharma ● LinkedIn: https://www.linkedin.com/in/bigidea/ Listen to more fantastic podcast episodes: https://podcast.ideapharma.com/ Don’t forget to Subscribe, Rate, Review, Like, and Share! To listen to more fantastic podcast episodes: https://podcast.ideapharma.com/

Welcome to another incredible episode of the IDEA Collider│Pharma Book Club series with your host Mike Rea. Today, Annie Duke joins us on the show to discuss her latest book, “Quit: The Power of Knowing When to Walk Away.” Annie is an Author, Professional Speaker, Decision Strategist & co-founder of The Alliance for Decision Education, a non-profit whose mission is to improve lives by empowering students through decision skills education. In the episode, Annie Duke delves into the motivation behind her latest book, “Quit,” when quitting is a valuable option rather than sticking around, grit versus willingness to quit, and Stewart’s Butterfield’s Quit story before founding Slack. In addition, Annie expounds on the fear of changing your mind and why most people worry about failing instead of winning. Ultimately, she delves into the Monkey & Pedestal Model, three reasons behind building the pedestal, the kill criteria & why you should have a quitting coach! Tune in for more! During this episode, you will learn about; [00:00:33] Introducing today’s guest [00:01:37] What motivated Annie in writing her book Quit as opposed to Thinking in Bets that lead to decision making [00:06:40] The difference between grit & willingness to quit [00:09:27] Why eight times more people die on the descent of Mt. Everest than climbing [00:18:53] Muhammad Ali is the embodiment of showing how in one circumstance, Grit can be a virtue & in the other circumstance, a downfall [00:30:20] Stewart Butterfield’s story from one of the world’s greatest quitter to founding Slack [00:39:37] The fear of changing your mind & failing[00:48:36] The monkey & pedestal model [00:56:18] Three reasons behind building the pedestal [01:02:38] The kill criteria  & the idea of having a quitting coach [01:10:08] Does Annie act as a quitting coach? [01:18:51] The Reverse Sicilian concept [01:20:17] How to connect with Annie Duke Don’t forget to Follow, Rate, Review, Like, and Share Mentioned BooksThinking in Bets by Annie DukeQuit: The Power of Knowing When to Walk Away by Annie DukeGrit by Angela DuckworthInto Thin Air by Jon Krakauer Let’s Connect! Follow Alliance For Decision Education;Website: https://alliancefordecisioneducation.org/ Follow Annie Duke;Website: https://www.annieduke.com/Twitter: https://twitter.com/AnnieDukeLinkedIn: https://www.linkedin.com/in/annie-duke/ More ProductsFollow Mike Rea on;Website: https://www.ideapharma.com/Twitter: https://twitter.com/ideapharmaLinkedIn: https://www.linkedin.com/in/bigidea/ To listen to more amazing podcast episodes: https://podcast.ideapharma.com/

Welcome to another incredible episode of the IDEA Collider series with your host Mike Rea. Today the Chief Financial Officer at Recursion, Dr. Michael Secora, joins us on the show as we discuss the industrial revolution of drug discovery. Michael is a scientist and a former equity investor.In the episode, Michael delves into the reasons behind the incredibly fast growth at Recursion, the company’s mission of decoding biology to radically improve lives, the relatability of data, and how Recursion builds its various data sets for drug discovery. Moreover, he expounds on how Recursion stands out against its competitors in the tech industry, the unique demographics of the Recursion team, and what differentiates Recursion from other AI discovery companies.Tune in!During this episode, you will learn about;[00:23] Introducing today’s episode[01:29] About Michael Secora and Recursion as it is today[04:58] Recursion’s Mission on decoding biology to improve lives radically[08:48] Biotechnology versus BioPharma Companies[15:00] Relatability of Data[17:10] Recursion’s data sets & their contents[22:13] How many terabytes of data are they in executing each experiment[24:15] How Recursion stands out against competitors in the Tech environment[26:23] Michael’s approach to humility in the pharmaceutical industry[28:28] Demographics of the Recursion team[31:20] Recursion’s Hack Week[34:51] The difference between AI discovery companies & Recursion[40:11] A hint of Recursion incredible speed in delivering value proposition[47:47] Michael’s Book Recommendations[50:16] How to connect with Michael & Recursion` Don’t forget to Follow, Rate, Review, Like, and Share! Mentioned BooksJourney through Mathematics by Enrique A. GonzalezTeam of Teams by Gen. Stanley McChrystal, Tantum Collins, David Silverman & Chris FusselWhat is Life by SchrodingerLet’s Connect!Follow Recursion on;Website: https://www.recursion.com/LinkedIn: https://www.linkedin.com/company/recursion-pharmaceuticals/ Follow Michael SecoraLinkedIn: https://www.linkedin.com/in/michael-secora-phd/ More ProductsFollow Mike Rea on;Website: https://www.ideapharma.com/Twitter: https://twitter.com/ideapharmaLinkedIn: https://www.linkedin.com/in/bigidea/ To listen to more amazing podcast episodes: https://podcast.ideapharma.com/

The healthcare industry is moving towards a digital revolution. With the help of digital technology, healthcare providers can now provide better and more efficient services to their patients. Digital technology has also proven to have a positive impact on patient outcomes, as well as the cost of care. Companies such as Openwater, which focuses on creating the future of medical imaging, have been able to deliver life-saving technologies. Through the use of low-intensity ultrasound, Openwater has been able to treat diseases such as glioblastoma, depression, neurodegenerative diseases, and stroke.In this episode, Mary Lou Jepsen, the CEO and Founder of Openwater shares how Openwater started and what it deals with. Mary Jepsen also shares how her company has transformed healthcare through digital technology. Moreover, she discusses the operating and hiring principles of the company.   Tune in for more insights! Key Highlights[01:44] Meet our guest; Meet our guest; Mary Lou Jepsen, and hear her backstory[03:32] The contrast between Pharmaceutical Companies and companies such as Google & Facebook[05:18] How we can apply physics to create interference ability and be able to see into our bodies using camera chips used in smartphones instead of using huge and expensive MRI scanners[07:32] Why the One Laptop Per Child (OLPC) initiative didn’t work[09:35] How she co-created the world’s first holographic video system from an idea that seemed impossible  [12:07] Physicists’ predominant culture of looking for all the ways that they might be wrong and learning from that vs. Biologists’ culture of looking for any proof that they are right [17:05] Technology that uses low-intensity ultrasound on human brain organoids in glioblastoma cancer treatment which is better than chemotherapy [18:24] How did Openwater start, and what does the company deal with? [20:17] The use of technology to enable rapid identification of the large vessel occlusions to decrease the time to intervention in stroke victims[26:56] Severe depression treatment using a headset capable of focusing low-frequency ultrasound on the nerve cells in the brain, which is more effective than transcranial magnetic stimulation[31:42] The side effect of psychedelics in depression treatment  [37:00] Comparison between cost change in the consumer electronics industry and the healthcare industry  [40:21] The operating and hiring principles of the Openwater company[49:00] How to link with Mary Lou Jepsen Don’t forget to Follow, Rate, Review, Like, and Share! Let’s Connect!Follow Mary Lou Jepsen on her;Personal website:https://www.maryloujepsen.com/Company website: https://www.openwater.cc/LinkedIn: https://www.linkedin.com/in/majepsen/Twitter: https://twitter.com/mljmljmljFacebook: https://web.facebook.com/maryloujepsen?_rdc=1&_rdr More Products Follow Mike Rea on;Website: https://www.ideapharma.com/Twitter: https://twitter.com/ideapharmaLinkedIn: https://www.linkedin.com/in/bigidea/ To listen to more fantastic podcast episodes: https://podcast.ideapharma.com/

Welcome to another incredible episode of the IDEA Collider│Pharma Book Club series with your host Mike Rea. Today a competitive advantage expert, and CEO of Smart Advantage, Jaynie Smith, joins us on the show.  She delves into snippets in her book, Creating Competitive Advantage, & the role of competitive advantage in increasing sales and protecting profit margins. Moreover, she explains that it’s not about prices but your value proposition, understanding your customers' top three buying criteria, and competitive positioning.  Ultimately she discusses the power of competitive advantage, implementing metrics that quantify competitive ads and focusing on the company rather than product advantage.Tune in for more! During this episode, you will learn about;[00:20] Introducing today’s episode[01:27] About today’s guest, “Jaynie Smith.”[05:05] The process of unpacking & looking for opportunities[09:44] Does everyone in business understand why they are in business[11:45] Competitive advantage is closing deals & making money in an organization[13:43] Why companies don’t spend enough time listening to their customers[16:09] Building your value proposition[22:28] Competitive positioning[26:05] Do people give positioning the credit  that’s due in the business world[30:48] Do ad agencies get competitive positioning right?[32:20] Company versus product competitive advantage[35:57] Why companies  lose sight of things that matter most to their customers[38:52] Persistence in communication[40:58] How to connect with Jaynie Smith[41:40] Book recommendations from Jaynie Let’s Connect!Follow Jaynie Smith on;LinkedIn: https://www.linkedin.com/in/jayniesmith/Website: jayniesmith.comFollow Smart AdvantageWebsite: https://smartadvantage.com/More ProductsFollow Mike Rea on;Website: https://www.ideapharma.com/Twitter: https://twitter.com/ideapharma LinkedIn: https://www.linkedin.com/in/bigidea/To listen to more amazing podcast episodes: https://podcast.ideapharma.com/

Welcome to another incredible episode of the IDEA Collider│Pharma Book Club series with your host Mike Rea. Today we are joined by Sherine Khalil, the Vice President and Chief Business Officer for Valor Compounding Pharmacy. She talks about sterile and non-sterile compounding as well as her transition from the nonprofit world to academic medicine.Additionally, she delves into the major functional areas of compounding pharmacy, the reasons behind the decline in compounding pharmacy over the years, her source of ideas, and how she judges success. Moreover, Sherine expounds on the organizational structure within the pharmacy, how far she plans into the future, and her journey in business consulting. Tune in! During this episode, you will learn about;[01:23] About Sherine Khalil[05:36] Sherine’s transition from the nonprofit world to academic medicine[11:25] Is her curiosity self-directional?[13:55] About compounding pharmacy and its major function areas[15:55] Reasons for the decline in compounding pharmacy over the years[19:00] Sherine’s source of ideas. What’s her process of assessing development[21:10] Organizational structure  and hierarchy within the pharmacy[22:25] How she judges success. What will work or not work[23:54] How far Sherine plans into the future[28:06] What her Quarter 1 & 2 goals look like for her amidst covid in 2022[30:13] What’s in Sherine’s organizational structure that makes her more agile than other companies[32:19] Sherine’s biggest idea in telehealth[39:33] Sherine’s journey in business consultancy[44:29] Her source of motivation[46:36] Sherine’s book recommendations[48:04] One thing Sherine wishes she could have been asked[52:13] To connect with Sherine Let’s Connect!Follow Sherine Khalil on;LinkedIn: https://www.linkedin.com/in/sherinekhalilEmail: skhalil@vcprx.comFollow Valor Compounding Pharmacy;Website: https://valorcompounding.com/More ProductsFollow Mike Rea on;●        Website: https://www.ideapharma.com/●        Twitter: https://twitter.com/ideapharma●        LinkedIn: https://www.linkedin.com/in/bigidea/To listen to more amazing podcast episodes: https://podcast.ideapharma.com/

Welcome to another incredible episode of the IDEA Collider│Pharma Book Club series with your host Mike Rea. Today we are joined by Prof. Brian D Smith, a pharma innovation geek for the past 24 years. He talks about his latest book, “ New Drugs, Fair Prices,” and how to manage the pharmaceutical innovation ecosystem for sustainable and affordable new medicines.Additionally, he delves deep into discovery habitats and how every habitat contributes to the ecosystem for a sustainable and affordable supply of new medicines. Moreover, Brian expounds on an unhealthy ecosystem and three big goals to achieve in our ecosystems.Tune in!During this episode, you will learn about;[00:21] Introducing the show[01:17] About Brian Smith[04:41] Brian’s main focus in his latest book, “New Drugs, Fair Prices.”[09:20] A snippet of the introduction to Brian’s new book[14:58] Why the definition of terms was important all the way through his book[18:36] The selection pressure in the industry[18:57] The seven types of habitats and what they need to contribute to the ecosystem[22:30] The innovation habitat[25:00] Brian’s definition of an unhealthy ecosystem[28:46] Three big goals we need to achieve through our ecosystem[33:20] Ecosystems don’t just change. How do you understand and manage them?[42:00] Book recommendations for aspiring innovation and pharmaceutical geeks[46:52] How to connect with Brian SmithLet’s Connect!Follow Brian Smith on;Website: https://www.pragmedic.com/Youtube: https://www.youtube.com/watch?v=35HFWM6tbTcPodcast: https://podcasts.apple.com/us/podcast/darwins-medicine/id1551652841More ProductsFollow Mike Rea on;●        Website: https://www.ideapharma.com/●        Twitter: https://twitter.com/ideapharma●        LinkedIn: https://www.linkedin.com/in/bigidea/To listen to more amazing podcast episodes: https://podcast.ideapharma.com/

Welcome to another incredible episode of the IDEA Collider│Pharma Book Club series with your host Mike Rea. Today a tech pioneer, founder & CEO of Rapid Alpha joins us on the show as we discuss marketing intelligence & why business leaders can not ignore data quality. Matthew talks about his career path from intellectual property to where he is now, about Rapid Alpha, what innovation management entails, and how data works and impacts company decisions. Additionally, he expounds on the right KPIs for pharmaceuticals, platforms & tools for better data organization, creating value for your company as well as the future of data.Tune in for more!During this episode, you will learn about;[00:27] Introducing the episode[00:40] Know our guest “Matthew Wahlrab”[04:47] His career path from intellectual property to where he is now[12:00] How data works[16:55] Defining innovation management[21:16] How data impacts company decisions[22:15] About Matthew's company Rapid Alpha & what they do[24:48] Matthew’s special sources [26:29] Matthew’s approach to Green flags & who should be working where[29:49] Getting your timing right[32:22] The right KPIs for pharmaceuticals[37:49] Platforms & tools for better data organization[43:04] Creating value in an enterprise[47:52] The future of data[51:44] Book recommendations from Matthew[55:45] Best way to connect with Matthew Wahlrab[56:31] One question he wishes to have been askedLet’s Connect!Follow Matthew Wahlrab on;LinkedIn: https://www.linkedin.com/in/matthew-wahlrab/Follow Rapid Alpha on;Website: https://rapidalpha.com/LinkedIn: https://www.linkedin.com/company/rapidalpha/ More ProductsFollow Mike Rea on;●        Website: https://www.ideapharma.com/●        Twitter: https://twitter.com/ideapharma●        LinkedIn: https://www.linkedin.com/in/bigidea/To listen to more amazing podcast episodes: https://podcast.ideapharma.com/

Welcome to another incredible episode of the IDEA Collider│Pharma Book Club series with your host Mike Rea. Today, Tim Kight,  a long-life student of elite performance, coach, and Focus 3 CEO joins us on the show as we discuss developing leaders & strengthening organizational culture to achieve better results.Tim delves into the five drivers of organizational greatness, training your team on behavioral skills, rebuilding your company’s culture, and expanding your focus run. Additionally, he talks about replacing old habits with good ones, the twenty square ft principle, and stepping up to become an elite in your team! Tune in for more! During this episode, you will learn about;[00:27] Introducing the show[01:50] Tim’s background & experience in sports & business[05:45] Invention doesn’t become innovation all by itself.  What roles teams & organizations play[07:29] 5 drivers for organizational greatness[09:25] Talent recognition in organizations[11:26] What to consider when hiring -Job skills vs. behavior skills. [17:52] Leading with your heart in business[20:43] Rethinking & rebuilding a company’s clear, concise & compelling culture[23:13] A quick contrast between an athletic & business team[26:41] Planning for the future of your business.  The known versus the unknown of the company's future.[31:14] Expanding your focus run & 5 questions to ask yourself and your team[35:50] Unlearning to relearn your skill versus replacing old habits with good ones[38:00] Tim’s twenty square ft principle[45:37] A case study on changing culture, discipline & achieving good results[53:00] Stepping up, confronting that default mode, and becoming elite in your team[55:36] To connect with Tim Kight Don’t forget to Follow, Rate, Review, Like, and Share! Let’s Connect!Follow Tim Kight on;●        LinkedIn: https://www.linkedin.com/in/timothykight/●        Website:  https://focus3.com●        Twitter: @TimothyKight●        Email: tim@foucs3.comMore ProductsFollow Mike Rea on;●        Website: https://www.ideapharma.com/●        Twitter: https://twitter.com/ideapharma●        LinkedIn: https://www.linkedin.com/in/bigidea/To listen to more amazing podcast episodes: https://podcast.ideapharma.com/

Welcome to another amazing episode of the IDEA Collider│Pharma Book Club series with your host Mike Rea. In today’s episode, Mike is joined by John Waid. John is a thought leader, author, and CEO of a unique boutique global culture & leadership development firm. He talks about culture and the purpose of an organization.Additionally, he talks about the importance of knowing your; purpose, mission, values, and principles of behavior and why most professionals who are promoted based on their skill sets fail when promoted to leadership positions. Moreover, he shares how to start building a successful workplace culture.  Tune in! During this episode, you will learn about;[00:22] Episode introduction[00:36] Today’s focus; Asymmetric learning and its impact on culture[00:55] Know our guest; John Waid[03:01] What is culture?[05:41] The purpose of an organization[10:36] Examples of companies and their values[14:46] Why he came up with the principle of three values[16:34] The importance of respectful spirit value[19:19] Why you should know your; purpose, mission, values, and principles of behavior[22:16] Why most professionals who are promoted based on their skillsets fail when promoted to leadership positions[26:27] Chick-fil-A’s values and culture[32:31] Why one company outperforms the other[37:16] Can culture be built virtually? [40:25] How to start building a successful workplace culture [42:53] Disruption vs Innovation[45:09] How to connect with John Waid  Love the show? Follow, Rate, Review, Like, and Share!  Let’s Connect!Follow John Waid on;Website: https://www.corporatecultureconsulting.com/LinkedIn: https://www.linkedin.com/in/johnwaid/Facebook: https://www.facebook.com/c3culture/ More Products Follow Mike Rea on;Website: https://www.ideapharma.com/Twitter: https://twitter.com/ideapharmaLinkedIn: https://www.linkedin.com/in/bigidea/To listen to more amazing podcast episodes: https://podcast.ideapharma.com/

Welcome to another incredible episode of the IDEA Collider│Pharma Book Club series with your host Mike Rea. Today we are joined by a consultant, best-selling author, and one of the world’s top experts on strategy and innovation, Rita McGrath.In the episode, Rita talks to us about her transition from a political science career to innovation in the corporate venture, how to build an innovation program, challenges in implementation, and why you need multiple funding sources while championing an idea. Additionally, we delve into making that 10x shift in a company, discovery-driven planning, strategic inflection points & best books she would recommend.Tune in for more innovation insights![02:01] About Rita McGrath[05:10] Rita’s books[11:55] Tips for building an innovation program[16:10] Why do companies have one innovation process[18:45] Reasons companies prefer false confidence instead of the uncertain approach[27:40] How to get an organization to make a shift to a big place[34:11] Rita’s thoughts on creativity[37:25] Why you should have multiple sources  of funding & approval[37:54] Being future forward on failure & interrogating failure[43:48] Problems related to assumptions in planning[49:39] Discovery-driven planning[51:01] Strategic inflection points[55:05] Books Rita would recommend[57:16] This or that question (Disruption or innovation)[58:13] To connect with McGrath Mentioned BooksSeeing Around the Corners By Rita McGrathMarket Busters By Rita McGrathThe End of Competitive Advantage By Rita McGrathDiscovery-Driven Growth By Rita McGrathSeven Rules of Power By Jeffrey PfefferThinking Fast & Slow by Kahneman DanielHumor Seriously By Jennifer A Aker & Naomi Bagdonas Let’s Connect!To Connect With Rita McGrath;●    Website: https://www.ritamcgrath.com/●    Website: https://www.valize.com/ More ProductsFollow Mike Rea on;Website: https://www.ideapharma.com/Twitter: https://twitter.com/ideapharmaLinkedIn: https://www.linkedin.com/in/bigidea/To listen to more amazing podcast episodes: https://podcast.ideapharma.com/

Welcome to another incredible episode of the IDEA Collider│Pharma Book Club series with your host Mike Rea. Today we are joined by Andrew Hopkins, the Founder & CEO  of Exscientia, as he talks to us about the use of AI in drug discovery. In the episode, we delve into Andrew’s journey of developing better drug discovery methods, applying data mining in drug discovery, and the value of data integration in the pharmaceutical industry. Additionally, he expounds on what AI drugs look like and future plans for Exscientia. Tune in! During this episode, you will learn about;[01:12] Introducing Andrew Hopkins & his journey to his current role[06:27] Applying data mining approach & machine learning[12:10] What Andrew saw that others were not seeing[19:06] The value of data integration[22:02] The role of asking questions & finding answers in tech or data[26:46] How Hopkins addresses being referred to as the AI discovery group[33:08] Active learning approaches[39:06] What an AI drug looks like & what it’s better at[42:17] The future of AI drugs & Exscientia future plans in establishing clinics[46:34] What do the next couple of years look like regarding solutions Andrew wished he had 5-10 years ago? Don’t forget to Follow, Rate, Review, Like, and Share! Mentioned BooksIdeas-A History From Fire To Freud by Peter WatsonWhere Good Ideas Come From by Steven Johnson Let’s Connect!Follow Exscientia on;●        Website: https://www.exscientia.ai/●    LinkedIn: https://www.linkedin.com/company/ex-scientia/ More ProductsFollow Mike Rea on;Website: https://www.ideapharma.com/Twitter: https://twitter.com/ideapharmaLinkedIn: https://www.linkedin.com/in/bigidea/ To listen to more amazing podcast episodes: https://podcast.ideapharma.com/

In this incredible episode, Mike Rea is joined by Dr. John L. LaMattina. John is the former Senior Vice President of Pfizer Inc and President of Pfizer Global Research & Development. Additionally, he is a senior partner at PureTech Health and an author. He talks about the misconception about Pfizer’s profiteering from the pandemic and the drug pricing in America. John also discusses how Gilead’s Sovaldi drug for hepatitis C became overpriced in the US and the effects of insurance companies on the drug market. Moreover, he talks about the misinformation about insulin and its pricing, NIH’s role in drug discovery research, and the profitability of the pharma industry.Tune in! During this episode, you will learn about;[00:22] Introduction to the show[0:42] Know our guest; Dr. John L. LaMattina, and why he has authored his books[04:58] Misconception about Pfizer’s profiteering from the pandemic[08:13] Drug pricing in America[12:35] Gilead’s Sovaldi drug for hepatitis C and how it became overpriced in the US more than in other countries [19:57] The cost-effectiveness of PCSK9 in regulating (low-density lipoprotein) LDL cholesterol[21:42] Effect the insurance companies have had on the drug market [26:09] Value of  the ‘me-too’ drugs [30:01] The inefficiency of the flu vaccines [33:03] The funding for early-stage mRNA vaccines [34:23] The input of the FDA and CDC in the manufacture of mRNA vaccines [37:46] What is NIH’s role in drug discovery research?[38:13] The process and cost of drug discovery; from idea to getting the drug approved[42:39] Misinformation about insulin and its pricing [47:21] Is the value vs. affordability of medicines a reputation challenge or a  commercial challenge for the industry?[51:31] What’s the profitability of the pharma industry?[59:48] Recommended reading [01:02:38] How to connect with us Don’t forget to Subscribe, Rate, Review, Like, and Share! Resources MentionedBook; Pharma and Profits by John L. LaMattina Book; Devalued and Distrusted by John L. LaMattinaBook; Drug Truths by John L. LaMattinaBook; The Great American Drug Deal by Peter Kolchinsky  Let’s Connect!Website: https://www.johnlamattina.com/Twitter: https://twitter.com/john_lamattinaLinkedIn: https://www.linkedin.com/in/john-lamattina-2985a9b/ More Products Follow Mike Rea on;Website: https://www.ideapharma.com/Twitter: https://twitter.com/ideapharmaLinkedIn: https://www.linkedin.com/in/bigidea/ To listen to more fantastic podcast episodes: https://podcast.ideapharma.com/